[go: up one dir, main page]

WO2003068268A3 - Treatment, diagnosis and imaging of disease - Google Patents

Treatment, diagnosis and imaging of disease Download PDF

Info

Publication number
WO2003068268A3
WO2003068268A3 PCT/EP2003/001461 EP0301461W WO03068268A3 WO 2003068268 A3 WO2003068268 A3 WO 2003068268A3 EP 0301461 W EP0301461 W EP 0301461W WO 03068268 A3 WO03068268 A3 WO 03068268A3
Authority
WO
WIPO (PCT)
Prior art keywords
mcl
cells
moiety
imaging
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/001461
Other languages
French (fr)
Other versions
WO2003068268A2 (en
Inventor
Sara Ek
Carl Arne Krister Borrebaeck
Mats Ehinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203480A external-priority patent/GB0203480D0/en
Priority claimed from GB0215095A external-priority patent/GB0215095D0/en
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Priority to AU2003210266A priority Critical patent/AU2003210266A1/en
Publication of WO2003068268A2 publication Critical patent/WO2003068268A2/en
Publication of WO2003068268A3 publication Critical patent/WO2003068268A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.
PCT/EP2003/001461 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease Ceased WO2003068268A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210266A AU2003210266A1 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203480.9 2002-02-14
GB0203480A GB0203480D0 (en) 2002-02-14 2002-02-14 Treatment diagnosis and imaging of disease
GB0215095A GB0215095D0 (en) 2002-06-29 2002-06-29 Treatment, diagnosis and imaging of imaging of disease
GB0215095.1 2002-06-29

Publications (2)

Publication Number Publication Date
WO2003068268A2 WO2003068268A2 (en) 2003-08-21
WO2003068268A3 true WO2003068268A3 (en) 2004-03-11

Family

ID=27736212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001461 Ceased WO2003068268A2 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Country Status (2)

Country Link
AU (1) AU2003210266A1 (en)
WO (1) WO2003068268A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
ATE423200T1 (en) * 2003-10-30 2009-03-15 Kazusa Dna Res Inst Foundation NEW PLEXIN POLYPEPTIDE, DNA CODING IT AND USE THEREOF
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
KR102153374B1 (en) 2012-03-15 2020-09-10 얀센 바이오테크 인코포레이티드 Human anti-cd27 antibodies, methods, and uses
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2002004021A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2002004021A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EK S. ET AL: "Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.", CANCER RESEARCH, (1 AUG 2002) 62/15 (4398-4405). REFS: 62 ISSN: 0008-5472 CODEN: CNREA8, 1 August 2002 (2002-08-01), XP002254996 *
ROBETORYE R S ET AL: "Microarray analysis of B-cell lymphoma cell lines with the t(14;18)", JOURNAL OF MOLECULAR DIAGNOSTICS 2002 UNITED STATES, vol. 4, no. 3, 2002, pages 123 - 136, XP002254997, ISSN: 1525-1578 *

Also Published As

Publication number Publication date
WO2003068268A2 (en) 2003-08-21
AU2003210266A8 (en) 2003-09-04
AU2003210266A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
EP2619321B1 (en) Biomarkers for differentiating melanoma from benign nevus in the skin
RU2008108907A (en) METHOD FOR PREDICTING A RESPONSE TO TREATMENT
KR20120065959A (en) Markers for predicting gastric cancer prognostication and method for predicting gastric cancer prognostication using the same
JP2009540803A5 (en)
HK1206796A1 (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2004091384A3 (en) Erbb surface receptor complexes as biomarkers
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
KR20210049117A (en) Bronchial Precancerous Lesion Severity and Methods Related to Progression
CN106662543B (en) Non-invasive genetic mutation testing in lung cancer patients
CN105190313B (en) With the relevant marker of WNT inhibitor
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
PT1994410E (en) Methods for early detection of cancer
EP2293075A3 (en) Method for diagnosing neuro-degenerative disease
WO2004063712A3 (en) Methods for diagnosis and prognosis of cancer
Yeh et al. H. pylori cagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin α5β1 related with gastric carcinogenesis
ATE419533T1 (en) METHOD/PREPARATION FOR DETECTING PANCREATIC CANCER
DE60306517D1 (en) METHOD FOR DETECTING AND QUANTIFYING TUMOR CELLS DERIVED FROM TOMORROWING TUMOR CELLS
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
CN109402252A (en) Acute myelogenous leukemia risk assessment gene marker and application thereof
EP1159614A4 (en) Diagnostic methods for asthma
WO2007101676A3 (en) Treatment, diagnosis and imaging of mantle cell lymphoma
Todorović-Raković et al. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer
US20110151469A1 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
Schobesberger et al. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores
Subramaniam et al. Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP